Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
-
New York, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association today announced the agenda including tracks and Chairs for the 2025 MDA Clinical & Scientific Conference being held...
-
VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Fitness World Canada and its community successfully raised $20,000 in September for their partnership with Augie’s Quest, an...
-
New York, Oct. 31, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) proudly highlights National Family Caregivers Awareness Month this November. MDA's month-long campaign emphasizes...
-
New York, Oct. 30, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today kicked off its largest annual Holiday Retail Campaign, spanning thousands of retail locations nationwide...
-
New York, Oct. 28, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association and the Players Trust, the charitable arm of the Major League Baseball Players Association, are thrilled to announce...
-
LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
-
Austin, TX, USA, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Heavy Metal Testing Market Size, Trends and Insights By Type (Arsenic, Cadmium,...
-
New York, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) is proud to announce a new clinical research grant of $500,000 over three years, awarded to Sabrina Paganoni,...
-
ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of...